At Assentus Biogenics, research is the foundation of our commitment to innovative and patient-centric healthcare solutions. We continuously strive to bridge the gap between scientific discovery and practical therapeutics through focused research, evidence-based development, and advanced formulation technologies.
Our research initiatives are designed to address evolving healthcare challenges by developing safe, effective, and quality-driven products across pharmaceuticals, nutraceuticals, wound care, regenerative medicine, and wellness segments. With a strong emphasis on innovation, we aim to create solutions that improve patient outcomes and enhance quality of life.
Focus Areas of Research
- Advanced anti - xerosis formulations
- Wound healing and tissue regeneration
- Osteoarthritis and pain management
- Nutraceutical and wellness solutions
- Bioactive compounds and targeted therapeutics
- Innovative delivery systems and product optimization
Focus Areas of Research
Our R&D activities are supported by scientific collaboration, market understanding, and continuous technological advancement. From conceptualization and formulation to validation and commercialization, every stage of development follows a rigorous process focused on quality, safety, and efficacy.
Through our research ecosystem, we aim to:
- Develop differentiated and value-driven healthcare products
- Enhance therapeutic effectiveness through innovation
- Promote evidence-based healthcare solutions
- Support sustainable and scalable product development
- Deliver affordable and accessible healthcare options
Dosinova Biotech –
Advancing Scientific Innovation
Dosinova Biotech, the research and innovation arm associated with Assentus Biogenics, is actively engaged in pioneering work in regenerative medicine, wound healing, and osteoarthritis care. As a DPIIT-recognized startup, Dosinova Biotech focuses on translating cutting-edge scientific research into impactful healthcare solutions.
By integrating modern biotechnology, bioactive research, and evidence-based innovation, the organization continues to explore new therapeutic possibilities that can transform patient care.
Dosinova Biotech is proudly incubated at BioNEST, benefiting from the mentorship of Prof. Dr. Quazi Syed Zahiruddin, Co-Principal Investigator at BioNEST DMIHER and Executive Director, Directorate of Research & Innovation, DMIHER (DU). His expertise in innovation, translational research, startup incubation, and academia-industry collaboration provides valuable strategic guidance, helping Dosinova accelerate the development and commercialization of science-backed healthcare solutions while strengthening our commitment to research excellence and innovation.
Collaborative Research Approach
At Assentus Biogenics, we believe collaboration accelerates innovation. We actively work with healthcare professionals, research organizations, manufacturing partners, and scientific institutions to strengthen product development and expand therapeutic opportunities.
Our collaborative model encourages:
- Knowledge-driven innovation
- Scientific validation and clinical relevance
- Faster development pathways
- Improved healthcare accessibility
- Long-term sustainable healthcare solutions
Collaborative researcher : Dr. Shreya Mehrotra, Ph.D., Founder of Neelanvi Health Private Limited. With over 12 years of expertise in biomaterials, nutraceuticals, and regenerative medicine, Dr. Mehrotra brings a strong focus on developing innovative, science-driven healthcare solutions that address unmet clinical needs. Together, we drive Assentus commitment to translating cutting-edge research into meaningful patient outcomes across areas such as oncology, regenerative medicine, and supportive care.
Our Vision for Research
We envision a future where innovation, science, and compassion work together to create meaningful healthcare advancements. Through continuous research and responsible development, Assentus Biogenics remains committed to delivering solutions that support healthier lives and a better tomorrow.By integrating modern biotechnology, bioactive research, and evidence-based innovation, the organization continues to explore new therapeutic possibilities that can transform patient care.
